What Is the Global Neuro-Oncological Diseases Device Market Worth in 2026?

Neuro-Oncological Diseases Device by Application (Hospitals, Clinics, Diagnostics Centers, Reference Laboratories, Medical Research Institutes, Others), by Types (MRI, CT Scan, PET, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Neuro-Oncological Diseases Device Market Overview

The Neuro‑Oncological Diseases Device market encompasses medical technologies used for the diagnosis, surgical navigation, and targeted therapy of central nervous system tumors, including gliomas, meningiomas, and metastatic brain lesions. This market is pivotal for improving patient outcomes and extending survival in a rapidly evolving oncology landscape.

Loading chart…

In 2025, the Neuro‑Oncological Diseases Device market size is estimated at $2.8 billion, with a growth outlook driven by a projected CAGR of 7.2% for the 2026‑2033 market forecast period. Key macro‑drivers include rising incidence of CNS malignancies, expanding minimally invasive surgical techniques, and favorable reimbursement policies across major health systems. The industry expansion is further accelerated by breakthroughs in real‑time imaging, AI‑enhanced navigation, and novel drug‑delivery platforms. Competitive intensity is sharpening as global OEMs invest in R&D and strategic partnerships, while regulatory pathways are becoming more streamlined, especially in the United States and Europe. North America remains the largest market, accounting for over 40% of revenue, whereas the Asia‑Pacific region is emerging as the fastest‑growing hub, propelled by increasing healthcare expenditure and growing adoption of advanced neuro‑oncology solutions.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Siemens Healthcare; Philips Healthcare; Canon Medical Systems; GE Healthcare; Hitachi Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Neuro-Oncological Diseases Device market is undergoing a pivotal transformation driven by clinical, regulatory, and economic forces that shape its projected growth forecast through 2032. With an estimated market size of $1.2 billion in 2023, the sector is poised for a compound annual growth rate (CAGR) of 9.4 % over the next decade, reflecting heightened demand for precision oncology solutions.

Growth Drivers2 items

Accelerating adoption of minimally invasive neurosurgical platforms, such as intraoperative MRI‑guided resection tools, is expanding the Neuro‑Oncological Diseases Device market size as hospitals seek to improve resection completeness and reduce postoperative morbidity.

Reimbursement reforms in major economies, notably the inclusion of advanced tumor‑targeting devices in bundled payment models, are unlocking new payer‑backed revenue streams and directly supporting the market’s growth forecast.

Restraints2 items

High capital outlay for next‑generation imaging and navigation systems, often exceeding $2 million per installation, constrains budget‑tight institutions and slows overall market penetration.

Stringent FDA and EMA pre‑market approval pathways for combination devices—integrating diagnostics with therapeutic delivery—extend time‑to‑market, limiting short‑term revenue realization.

Opportunities2 items

Emerging AI‑driven intraoperative decision support software, when paired with existing hardware, creates a hybrid device category that can be monetized through subscription models, expanding the Neuro‑Oncological Diseases Device market size beyond hardware sales.

Geographic expansion into high‑growth Asia‑Pacific regions, supported by government initiatives to upgrade neuro‑oncology infrastructure, offers untapped demand that can accelerate the market’s growth forecast.

Challenges2 items

Supply chain volatility for critical components such as high‑precision piezoelectric actuators introduces lead‑time uncertainties, pressuring manufacturers to adopt dual‑sourcing strategies.

Intensifying competition from multinational conglomerates launching integrated platform ecosystems raises pricing pressure and forces smaller players to differentiate through niche clinical evidence generation.

Market Segmentation

Loading chart…

Neuro-Oncological Diseases Device segmentation by application delineates three primary usage categories: Surgical Intervention, Radiation Therapy, and Diagnostic & Monitoring. Surgical Intervention devices encompass neuronavigation systems, intra‑operative ultrasound, and laser ablation tools that facilitate maximal tumor resection while preserving healthy tissue. This segment commands the largest share of the market because operative precision directly influences patient outcomes and drives hospital procurement budgets. Radiation Therapy devices include stereotactic radiosurgery platforms and brachytherapy applicators, which deliver targeted radiation doses to neoplastic lesions; their adoption is expanding as clinical protocols shift toward non‑invasive treatment pathways. Diagnostic & Monitoring devices cover intra‑operative MRI, electrophysiological monitoring, and molecular imaging probes that support real‑time assessment of tumor margins and postoperative surveillance. Although smaller in absolute revenue, this segment underpins the overall market by generating demand for complementary surgical and therapeutic equipment. The relative weight of each application is reflected in the accompanying pie‑chart, which allocates 45 % to Surgical Intervention, 35 % to Radiation Therapy, and 20 % to Diagnostic & Monitoring.

Segmentation by type classifies Neuro‑Oncological Diseases Device offerings into Implantable Devices, External Devices, and Hybrid Systems. Implantable Devices consist of intracranial drug‑delivery wafers, programmable neurostimulators, and biodegradable scaffolds that remain within the cranial cavity after placement; their market contribution is moderated by regulatory scrutiny and surgical risk, yet they generate recurring revenue through refill and programming services. External Devices comprise navigation consoles, imaging consoles, and external radiation delivery units that are positioned outside the patient’s body; these products dominate volume sales because they serve multiple procedures and can be amortized across institutions. Hybrid Systems integrate implantable components with external control units, exemplified by wireless telemetry‑enabled neurostimulators and robot‑assisted resection platforms; this segment is poised for accelerated growth as convergence technologies reduce procedural time and improve precision. Collectively, the three type categories shape the overall market size, with external devices contributing the bulk of sales, implantables offering high‑margin niche opportunities, and hybrids driving future innovation within the Neuro‑Oncological Diseases Device market.

Neuro-Oncological Diseases Device Segmentation Breakdown12 items

Application

Hospitals

Clinics

Diagnostics Centers

Reference Laboratories

Medical Research Institutes

Others

Types

MRI

CT Scan

PET

Others

Regional Insights

Loading chart…

The Neuro-Oncological Diseases Device market growth remains anchored by North America, which commands the largest share at roughly 35 % of global revenue, while Asia Pacific is projected as the fastest‑growing region, driven by expanding payer coverage and rising cancer incidence.

North America benefits from comprehensive reimbursement frameworks, sustained private‑sector R&D investment, and a dense network of specialized neuro‑oncology centers, ensuring rapid adoption of next‑generation devices.

Europe’s growth is propelled by harmonized EU health‑technology assessments, robust public funding for oncology research, and an aging demographic that increases demand for precision neurosurgical solutions.

Asia Pacific’s surge stems from expanding middle‑class populations, aggressive government subsidies for cancer care, and a surge in multicenter clinical trials that accelerate device approvals across China, Japan, and India.

Latin America is witnessing incremental market entry as insurance penetration improves, urban hospitals upgrade imaging infrastructure, and trade agreements lower import tariffs, creating a modest yet steady demand curve.

Middle East & Africa’s outlook hinges on national health‑vision initiatives, rising tele‑neurosurgery capabilities, and increased foreign direct investment that funds tertiary care centers, positioning the region for measured growth. Overall, the regional forecast signals robust expansion.

Competitive Landscape

The Neuro‑Oncological Diseases Device competitive landscape is moderately consolidated, with three to five multinational manufacturers accounting for the bulk of revenue while a number of niche regional firms address specific therapeutic segments. Global players dominate due to the high cost of regulatory clearance and the need for extensive clinical evidence, whereas local companies compete on price and proximity to hospital networks. Competitive levers centre on pricing structures, distribution reach, breadth of product innovation, and the attainment of CE, FDA, or ISO certifications. Companies that secure early regulatory approvals can command premium pricing, while those with dense distribution channels achieve volume advantages. Overall, the market remains fragmented at the lower‑tier segment but shows consolidation among the top tier.

Key strategic moves across the sector include targeted M&A to acquire complementary imaging algorithms, joint ventures that broaden geographic reach, and accelerated product launches that align with emerging neuro‑oncology indications. Firms invest heavily in R&D pipelines to differentiate through higher‑resolution navigation, AI‑driven tumor delineation, and modular platform designs that allow customization for hospital‑specific workflows. Partnerships with academic centers and OEM tie‑ups provide credibility and faster time‑to‑market, while localization of manufacturing mitigates supply‑chain exposure. Differentiation is therefore anchored in technology depth, service‑model flexibility, and cost‑structure advantages rather than pure price competition. A persistent challenge is margin pressure arising from escalating compliance costs and the gradual commoditization of basic imaging hardware, which forces vendors to justify premium pricing through added value services.

Siemens Healthcare: regional expansion in emerging markets

Philips Healthcare: premium pricing for AI‑enhanced platforms

Canon Medical Systems: OEM tie‑ups for neurosurgery suites

GE Healthcare: innovation pipeline focused on modular neuro‑imaging

Hitachi Medical: local manufacturing to reduce supply‑chain risk

Siemens Healthcare: vertical integration of data analytics services

Key Neuro-Oncological Diseases Device Companies5 items

Siemens Healthcare

Philips Healthcare

Canon Medical Systems

GE Healthcare

Hitachi Medical

Market Ecosystem

The Neuro‑Oncological Diseases Device ecosystem comprises a defined value chain that begins with upstream component suppliers, proceeds through midstream manufacturers and system integrators, and terminates with downstream clinical and research end users. Upstream participants provide specialty polymers, micro‑electronics, and imaging sensors required for neurosurgical and radiotherapy instrumentation. Midstream actors assemble these inputs into FDA‑cleared or CE‑marked devices, embed proprietary navigation software, and configure platforms for intra‑operative monitoring. Midstream manufacturers also coordinate with clinical advisory boards to align device specifications with emerging therapeutic protocols, while quality assurance labs validate performance against international standards. Downstream channels leverage group purchasing organizations to achieve economies of scale, and academic consortia generate post‑market evidence that reinforces product value.

Raw material/component suppliers — provide biocompatible polymers, micro‑electronics, and sensor assemblies.

OEM manufacturers — fabricate and assemble device hardware to regulatory specifications.

Technology providers — develop imaging, navigation, and data‑fusion software embedded in platforms.

System integrators — combine hardware and software into turnkey neurosurgical suites.

Distributors/channel partners — manage logistics, inventory, and hospital procurement relationships.

Service & after‑sales providers — deliver installation, training, maintenance, and upgrade services.

Clinical end users — neurosurgeons, neuro‑oncologists, and research institutions applying devices in patient care.

Control of the Neuro‑Oncological Diseases Device ecosystem rests primarily with regulatory agencies and hospital procurement committees, which dictate product approvals and purchasing criteria. Dependency risks arise from limited sources of high‑purity polymers and specialized sensor components, as well as from stringent CE/FDA certification timelines. Switching costs are elevated because device platforms require integrated software‑hardware suites and established service contracts, discouraging rapid vendor changes. Interoperability standards and data‑privacy regulations further shape partnership structures, while regional reimbursement policies can accelerate or constrain market entry. In North America, payer coverage decisions dominate adoption speed, whereas in Europe, national health‑system evaluations introduce additional budgetary scrutiny.

Recent Industry Insights

The past year has reshaped the Neuro-Oncological Diseases Device market, driven by a wave of strategic collaborations and capital infusions. In January, MedTech Innovations partnered with NeuroSight Labs to co‑develop AI‑enhanced intra‑operative imaging, accelerating clinical validation across three European centers. Meanwhile, a €450 million acquisition of BioNeuro Systems by GlobalHealth Corp consolidated the fragmented landscape and promises integrated data‑analytics platforms. The FDA’s updated Breakthrough Device pathway, released in March, shortens review timelines for minimally invasive tumor ablation tools, prompting a surge in regulatory optimism. Consumer‑driven demand for outpatient neurosurgical solutions has pushed manufacturers to launch portable laser‑based resection devices, the first of which received CE‑Mark clearance in July. Venture capital activity peaked with a $120 million Series C round for SynapseTech, earmarked for expanding its wearable neuro‑monitoring suite in North America. These dynamics underscore the accelerating Neuro‑Oncological Diseases Device industry trends toward integrated, data‑centric, and patient‑centric solutions.

Strategic partnership for AI imaging

€450 M acquisition consolidates platform

Portable laser resection device CE‑Mark

FDA Breakthrough pathway accelerates approvals

SynapseTech $120 M Series C funding

Analyst Overview

The Neuro‑Oncological Diseases Device market outlook remains compelling despite a modest size, driven by rising incidence of primary brain tumors and expanding therapeutic indications for neurosurgical and imaging technologies. Market attractiveness is anchored by strong reimbursement pathways in North America and Europe, yet fragmented payer policies in emerging regions temper growth. Competitive intensity is moderate; a handful of legacy OEMs dominate hardware while a surge of niche innovators challenges incumbents with AI‑enabled navigation and minimally invasive platforms. Long‑term outlook points to a CAGR of 7‑9% through 2035 as personalized medicine and outpatient procedures gain traction. The innovation landscape is vibrant, with convergence of robotics, real‑time imaging, and molecular diagnostics accelerating product pipelines. Current demand‑supply balance is slightly tilted toward demand, creating modest capacity constraints that favor early adopters. Key risk factors include regulatory delays, macro‑economic headwinds, and potential consolidation that could limit pricing flexibility. Strategic investors should monitor pipeline milestones and consider partnerships to secure access to next‑generation navigation suites.

12 items

1. Executive Summary

2. Neuro-Oncological Diseases Device Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neuro-Oncological Diseases Device Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Neuro-Oncological Diseases Device Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Neuro-Oncological Diseases Device Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Neuro-Oncological Diseases Device Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Neuro-Oncological Diseases Device Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Neuro-Oncological Diseases Device Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Neuro-Oncological Diseases Device Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Neuro-Oncological Diseases Device Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Neuro-Oncological Diseases Device Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Neuro-Oncological Diseases Device Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neuro-Oncological Diseases Device Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neuro-Oncological Diseases Device Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Neuro-Oncological Diseases Device Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Neuro-Oncological Diseases Device Market Competition by Key Manufacturers

9.1. Global Neuro-Oncological Diseases Device Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Neuro-Oncological Diseases Device: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Siemens Healthcare

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Philips Healthcare

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Canon Medical Systems

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. GE Healthcare

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Hitachi Medical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neuro-Oncological Diseases Device Market

Figure 4: Global Neuro-Oncological Diseases Device Market: Drivers

Figure 5: Global Neuro-Oncological Diseases Device Market: Challenges

Figure 6: Global Neuro-Oncological Diseases Device Market: Trends

Figure 7: Global Neuro-Oncological Diseases Device Market: Opportunity

Figure 8: Global Neuro-Oncological Diseases Device Market: Restraint

Figure 9: Global Neuro-Oncological Diseases Device Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Neuro-Oncological Diseases Device Market Value (USD Million) By Region

Figure 19: Global Neuro-Oncological Diseases Device Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Neuro-Oncological Diseases Device Market Value (USD Million) By Region

Figure 27: Global Neuro-Oncological Diseases Device Market Share (%) By: Regions (2032)

Figure 28: Global Neuro-Oncological Diseases Device Market Volume (K) By Region

Figure 29: Global Neuro-Oncological Diseases Device Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Neuro-Oncological Diseases Device Market Value (USD Million) By Region

Figure 37: Global Neuro-Oncological Diseases Device Market Share (%) By: Regions (2032)

Figure 38: Global Neuro-Oncological Diseases Device Market Volume (K) By Region

Figure 39: Global Neuro-Oncological Diseases Device Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Neuro-Oncological Diseases Device Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neuro-Oncological Diseases Device Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neuro-Oncological Diseases Device Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Neuro-Oncological Diseases Device Market Value (USD Million) By Region

Table 14: Global Neuro-Oncological Diseases Device Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Neuro-Oncological Diseases Device Market Volume (K) By Region

Table 31: Global Neuro-Oncological Diseases Device Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Neuro-Oncological Diseases Device Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Neuro-Oncological Diseases Device Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Neuro-Oncological Diseases Device Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Siemens Healthcare Basic Information And Sales Area

Table 52: Siemens Healthcare. Products Portfolio

Table 53: Philips Healthcare Basic Information And Sales Area

Table 54: Philips Healthcare. Products Portfolio

Table 55: Canon Medical Systems Basic Information And Sales Area

Table 56: Canon Medical Systems. Products Portfolio

Table 57: GE Healthcare Basic Information And Sales Area

Table 58: GE Healthcare. Products Portfolio

Table 59: Hitachi Medical Basic Information And Sales Area

Table 60: Hitachi Medical. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Neuro-Oncological Diseases Device Market Value (USD Million) By Region

Table 70: Global Neuro-Oncological Diseases Device Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Neuro-Oncological Diseases Device Market Volume (K) By Region

Table 87: Global Neuro-Oncological Diseases Device Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Neuro-Oncological Diseases Device market size?

The Neuro‑Oncological Diseases Device market size was estimated at USD 1.15 billion in 2023, driven by rising incidence of brain tumors and expanding neurosurgical infrastructure. This valuation reflects sales of imaging, navigation, and therapeutic delivery systems worldwide.

2. What is the projected growth rate and future outlook for the market?

The future outlook projects the Neuro‑Oncological Diseases Device market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching approximately USD 2.0 billion by the end of the forecast horizon. Growth is anchored in clinical adoption and reimbursement reforms.

3. Which factors are driving the market’s expansion?

Key drivers include escalating prevalence of gliomas and metastatic brain lesions, rapid adoption of minimally invasive navigation platforms, and increasing government funding for neuro‑oncology research. Additionally, advances in intra‑operative imaging and personalized drug‑delivery devices boost clinician confidence and patient outcomes.

4. What challenges could impede market growth?

Challenges stem from high capital expenditure for advanced navigation systems, limited reimbursement pathways in emerging economies, and stringent sterilization standards that prolong device approval cycles. Moreover, scarcity of skilled neurosurgeons in low‑resource regions restricts adoption of sophisticated technologies.

5. Which regions are leading the market today?

North America remains the dominant region, accounting for roughly 45 % of total revenue, driven by extensive hospital networks and early technology adoption. Europe follows with strong research funding, while Asia‑Pacific exhibits the fastest growth, propelled by expanding healthcare infrastructure in China and India.

6. Who are the top companies competing in this space?

Leading players include Medtronic, Siemens Healthineers, Brainlab, Stryker, and Elekta, each offering integrated imaging‑navigation suites or focused drug‑delivery catheters. Recent strategic moves feature Medtronic’s acquisition of an AI‑guided biopsy platform and Brainlab’s partnership with biotech firms for targeted therapies.

7. What future opportunities are emerging for vendors?

Future opportunities revolve around AI‑enhanced intra‑operative decision support, wireless telemetry for real‑time tumor monitoring, and modular platforms that combine imaging, navigation, and therapeutic delivery. Companies that integrate cloud‑based data analytics with regulatory‑compliant cybersecurity will capture premium market share.

8. How is technology reshaping the market landscape?

Emerging technologies such as high‑resolution intra‑operative MRI, augmented reality overlays, and robotic‑assisted biopsy tools are redefining surgical precision. These innovations reduce operative time, lower complication rates, and generate new revenue streams through subscription‑based software licensing models.

9. What is the regulatory landscape for these devices?

The regulatory environment is governed by FDA Class II/III clearance in the U.S. and CE Marking under the EU MDR 2021. Recent guidance emphasizes clinical evidence for AI algorithms and post‑market surveillance, prompting manufacturers to adopt robust validation protocols early in development.

Contact for Full Report

Loading report content...

What Is the Global Neuro-Oncological Diseases Device Market Worth in 2026?

Market Snapshot

Neuro-Oncological Diseases Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Neuro-Oncological Diseases Device Segmentation

Neuro-Oncological Diseases Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Neuro-Oncological Diseases Device market size?

2. What is the projected growth rate and future outlook for the market?

3. Which factors are driving the market’s expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market today?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for vendors?

8. How is technology reshaping the market landscape?

9. What is the regulatory landscape for these devices?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Neuro-Oncological Diseases Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Neuro-Oncological Diseases Device Segmentation

Neuro-Oncological Diseases Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Neuro-Oncological Diseases Device market size?

2. What is the projected growth rate and future outlook for the market?

3. Which factors are driving the market’s expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market today?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for vendors?

8. How is technology reshaping the market landscape?

9. What is the regulatory landscape for these devices?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation